Publications by authors named "Hanna Falk Hakansson"
Non-invasive imaging biomarkers (IBs) are warranted to enable improved diagnostics and follow-up monitoring of interstitial lung disease (ILD) including drug-induced ILD (DIILD). Of special interest are IB, which can characterize and differentiate acute inflammation from fibrosis. The aim of the present study was to evaluate a PET-tracer specific for Collagen-I, combined with multi-echo MRI, in a rat model of DIILD.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted using Sprague-Dawley rats to model drug-induced interstitial lung disease (DIILD) caused by bleomycin, with the aim of identifying imaging biomarkers for detection and quantification of the disease.
- The rats were imaged over multiple days using MRI and PET/CT, while bronchoalveolar lavage fluid and lung tissue samples were analyzed for inflammation and fibrotic changes.
- Results showed significant increases in lung inflammation and lesions within days of treatment, and two groups of responders were identified based on lung recovery, reinforcing the use of this animal model for studying DIILD and for potential clinical applications in lung injury assessment.
Preclinical in vivo models of lipopolysaccharide (LPS) -induced acute lung injury are commonly used to recapitulate pathophysiological features of chronic obstructive pulmonary disease and acute exacerbations. The LPS-induced lung inflammation is well described; however, whether the inflammatory response relates temporally to specific alterations in lung function has not been elucidated. We have investigated the effects of acute LPS inhalation in mice up to 96 h post LPS.
View Article and Find Full Text PDFBackground: Genetic factors influencing lung function may predispose to chronic obstructive pulmonary disease (COPD). The fibroblast growth factor 10 (FGF10) signalling pathway is critical for lung development and lung epithelial renewal. The hypothesis behind this study was that constitutive FGF10 insufficiency may lead to pulmonary disorder.
View Article and Find Full Text PDFBackground And Purpose: Beta(2)-adrenoceptor agonists (beta(2)-agonists) are important bronchodilators used in the treatment of asthma and chronic obstructive pulmonary disease. At the molecular level, beta(2)-adrenergic agonist stimulation induces desensitization of the beta(2)-adrenoceptor. In this study, we have examined the relationships between initial effect and subsequent reduction of responsiveness to restimulation for a panel of beta(2)-agonists in cellular and in vitro tissue models.
View Article and Find Full Text PDF